LOGIN  |  REGISTER
Assertio

Community Health Systems to Participate in 2023 RBC Capital Markets Global Healthcare Conference

May 09, 2023 | Last Trade: US$3.72 0.23 -5.82

FRANKLIN, Tenn. / May 09, 2023 / Business Wire / Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the RBC Capital Markets Global Healthcare Conference to be held May 16-17, 2023, at the InterContinental New York Barclay.

The Company will host a fireside chat presentation on Tuesday, May 16, 2023, at 11:30 a.m. ET, 10:30 a.m. CT. The fireside chat presentation will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website, www.chs.net, and a replay will be available using that same link.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 44 distinct markets across 15 states. CHS subsidiaries own or lease 78 affiliated hospitals with approximately 13,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page